Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10639172 | 1.00 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL29535380 | 0.87 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL416557 | 0.87 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL416558 | 0.87 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL7889282 | 0.87 | KDM4E (0.71) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13840607 | 0.85 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL28419799 | 0.85 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3110230 | 0.85 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| Cyclomethyltryptophan SCHEMBL10642614 | 0.85 | KDM4E (0.69) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27798629 | 0.85 | KDM4E (0.73) | KDM4ECYP2D6CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142322-A1 | 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-06-29 | — | — | US | claimed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| CN-110799652-A | Differentiated stem cells and agents for treating cancer | 米纳瓦生物技术公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-1438310-B1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060142322-A1 | 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-06-29 | — | — | US | disclosed |
| US-20050256181-A1 | Treating a viral disorder | ELIXIR PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | disclosed |
| US-6608193-B2 | Forming an intermediate by reacting the support-bound amino-substituted-tetrahydroisoquinoline compound with a reagent; and cyclizatively cleaving support-bound amino-substituted-tetrahydroisoquinoline compound | THE PROCTER & GAMBLE COMPANY | 2003-08-19 | — | — | US | disclosed |
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | PROCTER & GAMBLE COMPANY, THE | 2002-06-20 | — | — | US | disclosed |
| EP-0145304-B1 | TETRAHYDRO-BETA-CARBOLINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4628057-A | Tetrahydro-β-carboline derivatives and treatment of liver diseases | TANABE SEIYAKU CO., LTD. (JP) | 1986-12-09 | — | — | US | disclosed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142322-A1 | 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents | HTR3B, TH, IDO1 | KDM4E 358/4885CYP2D6 144/4885CYP1A2 172/4885 |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | KDM4E 970/4885CYP2D6 4379/4885CYP1A2 4081/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP2D6 4801/4885CYP1A2 4669/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP2D6 4801/4885CYP1A2 4669/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | KDM4E 1753/4885CYP2D6 3225/4885CYP1A2 2832/4885 |
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | ASNS, QPCT, DAO | KDM4E 493/4885CYP2D6 434/4885CYP1A2 373/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP2D6 4801/4885CYP1A2 4669/4885 |
| US-20050209300-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | KDM4E 3776/4885CYP2D6 2444/4885CYP1A2 1551/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP2D6 4801/4885CYP1A2 4669/4885 |
| US-20050256181-A1 | Treating a viral disorder | HAVCR2, EIF2AK2, RPL35 | KDM4E 3271/4885CYP2D6 615/4885CYP1A2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.